一种细胞类型选择性YM155前药物向受体相互作用蛋白激酶2诱导脑癌细胞死亡
Thomas J West1, Junfeng Bi2, Francisco Martínez-Peña1
1Department of Chemistry, The Scripps Research Institute, La Jolla, California 92037, United States.
Journal of the American Chemical Society
|April 5, 2023
概括
一种新型前药,aYM155,有效地向质母细胞,并增强大脑透. 这种前药在癌细胞内选择性地激活,通过向生存蛋白和受体相互作用蛋白激酶2 (RIPK2) 来抑制瘤生长.
科学领域:
- 癌症学
- 药理学
- 神经科学
背景情况:
- 质母细胞瘤 (GBM) 是一种具有有限治疗选择的侵袭性脑癌.
- YM155是一种强效的抗癌药物,抑制了生存,但缺乏细胞类型选择性,导致耐受性问题.
- 开发针对性治疗GBM仍然是一个关键的未满足需求.
研究的目的:
- 为改善质母细胞瘤治疗而设计和合成YM155的前药物.
- 评估aYM155的细胞杀伤活性,选择性和大脑透.
- 阐明YM155及其前的作用机制.
主要方法:
- 合成和YM155前药物 aYM155 的特征.
- 对来自患者的GBM细胞和EGFR增强细胞系的细胞杀死活性进行了体外评估.
- 质谱分析前药激活率和大脑透率 (大脑与血的比率).
- 在体内评估aYM155在骨头内GBM异种移植模型中的疗效.
主要成果:
- aYM155对GBM癌症干细胞和EGFR增强细胞系表现出强烈的细胞杀伤活性.
- 预制剂的激活取决于细胞类型,增强了转化细胞的选择性.
- 与原始药物YM155相比,aYM155表现出较好的脑传输.
- 通过RIPK2相互作用,YM155的抗癌作用与生存抑制和亡诱导有关.
- aYM155 在体内显著抑制了GBM瘤的生长,具有选择性的药理动力学效应.
结论:
- aYM155代表了质母细胞瘤的一种有前途的药物策略,提供了更强的选择性和大脑透.
- 前药的疗效由细胞类型的选择性激活和生存/ RIPK2通路的向介导.
- 对aYM155在治疗GBM中的潜在临床应用有必要进行进一步的研究.
更多相关视频
04:01Author Spotlight: Modeling Brain Tumors In Vivo Using Electroporation-Based Delivery of Plasmid DNA Representing Patient Mutation Signatures
Published on: June 23, 2023
1.8K
06:00Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
11.1K
相关概念视频
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
02:34Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
02:38Mitogens and the Cell Cycle
6.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K